犬の慢性心不全に対するマレイン酸エナラプリルの治療試験  [in Japanese] Clinical Evaluation of Enalapril Maleate for Treatment of Heart Failure in Dogs  [in Japanese]

Access this Article

Author(s)

Abstract

僧帽弁閉鎖不全を主因とするIII度或いはIV度の心不全を有する家庭飼育犬を用いてエナラプリルの有効性および安全性を評価する試験を国内20ヶ所の動物病院の協力を得て行った。年齢5~18歳,体重1.4~19.7kgの様々な品種および性別の犬136頭を供試し,無作為にエナラプリル投薬群とプラセボ対照群に振り分けた。エナラプリル群の供試犬にはエナラプリル0.25mg/kg1日1回の初期用量で7日間投薬した後,投薬後14日目まで0.5mg/kg1日1回に投与量を増量した。投薬回数の1日1回から1日2回への変更は投薬14日目の検査結果を基に獣医師の判断で行った。対照群の犬にはプラセボ錠を投与し,エナラプリル錠およびプラセボ錠の投薬は28日間行った。1頭を除き総ての供試犬に心不全の標準療法を獣医師の判断で行った。すなわち125頭(92%)の犬にフロセミドを最犬4mg/kg/日,125頭(92%)の犬にジゴキシンを最大10μg/kg/日の用量でそれぞれ投与した。対照群およびエナラプリル群の供試犬頭数はそれぞれ67頭および69頭で,その内対照群の46頭そしてエナラプリル群の57頭が試験を終了した。<BR>投薬28日後に行った検査結果では,総てのスコア化された検査項目(活動性,運動能力,食欲,咳の頻度,呼吸状態,肺水腫の程度,および心不全分類)の投薬開始前と比較した改善度がエナラプリル群の方が対照群に比べて統計学的に有意に優れていた。獣医師の判断による総合評価は投薬7,14および28日目総ての時点でエナラプリル群の方が対照群に比べて統計学的に有意に優れていた。血清生化学,電解質等の検査結果に関する両群間の有意差は認められなかった。エナラプリル投薬に起因する副作用は全く認められなかった。本試験結果から,エナラプリル0.25~0.5mg/kgを1日1回又は2回心不全の標準療法と併用する事によって心不全の臨床症状を安全に改善することが判明した。

A multi-center field study to assess the safety and efficacy of enalapril maleate (enalapril) in household dogs with naturally acquired Class III or Class IV heart failure caused mainly by mitral regurgitation was conducted at 20 animal hospitals in Japan. One hundred and thirty-six dogs of various breeds and each sex, aged 5 to 18 years and weighing 1.4 to 19.7 kg were included in the study and were randomly allocated to a vehicle control group (control group) or to an enalapril treatment group (enalapril group). Dogs in the enalapril group received the medication at the starting dose of approximately 0.25 mg/kg once a day (s.i.d.) for 7 days, followed by 0.5 mg/kg s.i.d., with an option to increase the dose on Day 14 to 0.5 mg/kg twice a day (b.i.d.) based on the results of physical examination and laboratory testing on Day 14. Dogs in the control group received vehicle tablets. Doses were administered for approximately 28 days. All but one dogs received standard therapy for congestive heart failure : 125 (92%) dogs received furosemide (maximum 4 mg/kg/day) and 125 (92%) dogs received digoxin (maximum 10μg/kg/day) at the discretion of the investigator. Sixtyseven and 69 dogs were allocated to the control group and the enalapril group, respectively. Forty-four (66%) dogs in the control group completed the study when compared to 57 (83%) dogs in the enalapril group. The improvement from baseline to Day 28 was significantly greater for dogs in the enalapril group than for those in the control group for all scored parameters: activity, mobility, appetite, coughing, respiratory effort, pulmonary edema, and class of heart failure. Overall evaluation judged by the investigators were significantly better for the enalapril-treated dogs than for the control dogs on Days 7, 14 and 28. No differences were observed between the enalapril group and the control group for changes in all laboratory testing parameters (serum chemistry, electrolytes, etc.). No adverse reactions attributable to enalapril treatment were observed. The results of the study demonstrate that enalapril administered at 0.25 to 0.5 mg/kg s.i.d. with standard therapy of heart failure improves the clinical signs associated with heart failure. There were no enalapril-related adverse reactions.

Journal

  • Advances in Animal Cardiology

    Advances in Animal Cardiology 29(1), 14-26, 1996-06

    Japanese Society of Veterinary Cardiology

References:  13

Cited by:  2

Codes

  • NII Article ID (NAID)
    10008286936
  • NII NACSIS-CAT ID (NCID)
    AN10192925
  • Text Lang
    JPN
  • Article Type
    Journal Article
  • ISSN
    09106537
  • NDL Article ID
    3995999
  • NDL Source Classification
    ZR22(科学技術--農林水産--畜産)
  • NDL Call No.
    Z18-1508
  • Data Source
    CJP  CJPref  NDL  J-STAGE  JASI 
Page Top